Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 20 11 2018
revised: 16 01 2019
accepted: 05 02 2019
pubmed: 19 2 2019
medline: 28 7 2020
entrez: 19 2 2019
Statut: ppublish

Résumé

There is inconsistency in the literature regarding the clinical effects of proton pump inhibitors (PPI) when added to dual antiplatelet therapy (DAPT) in subjects with coronary artery disease (CAD). We performed meta-analysis stratified by study design to explore these differences. 39 studies [4 randomized controlled trials (RCTs) and 35 observational studies) were selected using MEDLINE, EMBASE and CENTRAL (Inception-January 2018). In 221,204 patients (PPI = 77,731 patients, no PPI =143,473 patients), RCTs restricted analysis showed that PPI did not increase the risk of all-cause mortality (Risk Ratio (RR): 1.35, 95% Confidence Interval (CI), 0.56-3.23, P = 0.50, I Meta-analysis of RCTs endorsed the use of PPI with DAPT for reducing GI bleeding without worsening cardiovascular outcomes. These findings oppose the negative observational data regarding effects of PPI with DAPT.

Sections du résumé

BACKGROUND BACKGROUND
There is inconsistency in the literature regarding the clinical effects of proton pump inhibitors (PPI) when added to dual antiplatelet therapy (DAPT) in subjects with coronary artery disease (CAD). We performed meta-analysis stratified by study design to explore these differences.
METHODS AND RESULTS RESULTS
39 studies [4 randomized controlled trials (RCTs) and 35 observational studies) were selected using MEDLINE, EMBASE and CENTRAL (Inception-January 2018). In 221,204 patients (PPI = 77,731 patients, no PPI =143,473 patients), RCTs restricted analysis showed that PPI did not increase the risk of all-cause mortality (Risk Ratio (RR): 1.35, 95% Confidence Interval (CI), 0.56-3.23, P = 0.50, I
CONCLUSION CONCLUSIONS
Meta-analysis of RCTs endorsed the use of PPI with DAPT for reducing GI bleeding without worsening cardiovascular outcomes. These findings oppose the negative observational data regarding effects of PPI with DAPT.

Identifiants

pubmed: 30773427
pii: S1553-8389(19)30107-1
doi: 10.1016/j.carrev.2019.02.002
pmc: PMC7489463
mid: NIHMS1620969
pii:
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0
Proton Pump Inhibitors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1125-1133

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

N Engl J Med. 2001 Aug 16;345(7):494-502
pubmed: 11519503
PLoS One. 2014 Jan 08;9(1):e84985
pubmed: 24416326
J Clin Gastroenterol. 2008 Apr;42(4):368-72
pubmed: 18277903
Br J Clin Pharmacol. 2012 Nov;74(5):824-34
pubmed: 22364155
Chin Med J (Engl). 2011 Mar;124(6):856-61
pubmed: 21518592
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
BMJ. 2012 Jul 10;345:e4388
pubmed: 22782731
Catheter Cardiovasc Interv. 2012 Oct 1;80(4):556-63
pubmed: 22234956
Stat Med. 2002 Oct 15;21(19):2917-30
pubmed: 12325108
J Am Heart Assoc. 2013 Jan 15;2(1):e004564
pubmed: 23525436
Dig Dis Sci. 2010 Jul;55(7):1964-8
pubmed: 19731021
Coron Artery Dis. 2011 May;22(3):199-205
pubmed: 21358542
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Circulation. 2012 Feb 28;125(8):978-86
pubmed: 22261200
ISRN Cardiol. 2012;2012:692761
pubmed: 22792485
Int J Epidemiol. 2012 Jun;41(3):818-27
pubmed: 22461129
Circulation. 2011 Feb 8;123(5):474-82
pubmed: 21262992
Am J Cardiol. 2010 Mar 15;105(6):833-8
pubmed: 20211327
N Engl J Med. 2010 Nov 11;363(20):1909-17
pubmed: 20925534
Wien Med Wochenschr. 2012 Feb;162(3-4):67-73
pubmed: 22476595
Eur Cytokine Netw. 2010 Dec;21(4):257-63
pubmed: 21084246
Open Heart. 2015 Jun 30;2(1):e000248
pubmed: 26196021
Circ Cardiovasc Interv. 2011 Apr 1;4(2):162-70
pubmed: 21386091
Heart Vessels. 2013 May;28(3):292-300
pubmed: 22460241
Ann Intern Med. 2010 Sep 21;153(6):378-86
pubmed: 20855802
J Intern Med. 2012 Mar;271(3):257-63
pubmed: 21726302
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Thromb Haemost. 2010 Sep;104(3):626-32
pubmed: 20664905
Can J Cardiol. 2010 Feb;26(2):e54-7
pubmed: 20151060
PLoS One. 2016 Jan 04;11(1):e0145504
pubmed: 26727382
Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):47-55
pubmed: 25587094
Thromb Haemost. 2010 Dec;104(6):1211-8
pubmed: 20941464
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Am Heart J. 2016 Apr;174:95-102
pubmed: 26995375
BMC Cardiovasc Disord. 2017 Jan 5;17(1):3
pubmed: 28056809
J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228
pubmed: 25260718
Am J Cardiol. 2011 Mar 15;107(6):871-8
pubmed: 21247527
N Engl J Med. 2005 Mar 24;352(12):1179-89
pubmed: 15758000
Pharmacotherapy. 2010 Aug;30(8):787-96
pubmed: 20653354
J Thromb Thrombolysis. 2009 Oct;28(3):282-7
pubmed: 18830566
J Am Heart Assoc. 2015 Oct 29;4(11):
pubmed: 26514161
JAMA. 2009 Mar 4;301(9):937-44
pubmed: 19258584
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
PLoS One. 2015 Aug 27;10(8):e0135915
pubmed: 26313000
J Cardiovasc Med (Hagerstown). 2012 Dec;13(12):783-9
pubmed: 21252697
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Lancet. 2009 Sep 19;374(9694):989-997
pubmed: 19726078
Clin Cardiol. 2010 Mar;33(3):168-71
pubmed: 20235209
Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):636-41
pubmed: 23684576
Spine (Phila Pa 1976). 2003 Jun 15;28(12):1290-9
pubmed: 12811274
J Thromb Haemost. 2006 Nov;4(11):2508-9
pubmed: 16898956
Circ Cardiovasc Interv. 2015 Oct;8(10):
pubmed: 26458411
Am J Gastroenterol. 2012 Mar;107(3):389-96
pubmed: 22108447
Ann Intern Med. 2010 Mar 16;152(6):337-45
pubmed: 20231564
Rev Port Cardiol. 2010 Oct;29(10):1511-20
pubmed: 21265493
J Am Coll Cardiol. 2008 Jan 22;51(3):256-60
pubmed: 18206732
Pharmacotherapy. 2012 Sep;32(9):809-18
pubmed: 22744772
Circ J. 2012;76(1):71-8
pubmed: 22130313
Yakugaku Zasshi. 2010 Dec;130(12):1743-50
pubmed: 21139402

Auteurs

Safi U Khan (SU)

West Virginia University, Morgantown, WV, USA. Electronic address: safinmc@gmail.com.

Ahmad N Lone (AN)

West Virginia University, Morgantown, WV, USA.

Zain Ul Abideen Asad (ZUA)

University of Oklahoma, Oklahoma City, OK, USA.

Hammad Rahman (H)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Muhammad Shahzeb Khan (MS)

John H. Stroger, Jr. Hospital of Cook County, Chicago, OH, USA.

Muhammad A Saleem (MA)

Mercy Health, Janesville, WI, USA.

Adeel Arshad (A)

Unity Hospital/Rochester Regional Health System, Rochester, NY, USA.

Najma Nawaz (N)

Khyber Medical College, Peshawar, Pakistan.

Sudhakar Sattur (S)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Edo Kaluski (E)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH